Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
NCT06039176
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- LVAD
- Frailty
- GI Bleed
- Right Heart Failure
- Infections
- Hypertension
- Arrhythmias
- Stroke
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- International Consortium of Circulatory Assist Clinicians
- Last updated on ClinicalTrials.gov
- December 16, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCSF · San Francisco, CA
Florida · 1
- University of Florida · Gainesville, FL
Illinois · 1
- University of Chicago · Chicago, IL
Minnesota · 1
- Mayo Clinic-Rochester · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.